Episodes

Thursday Dec 14, 2023
E104: Sarilumab for PMR - The SAPHYR Study
Thursday Dec 14, 2023
Thursday Dec 14, 2023
Important trial on the podcast this week! I take a deep dive into the recently published SAPHYR study, which evaluated the use of the IL6 inhibitor sarilumab for patients with PMR. A few aggravating quibbles but overall a very useful trial and an important step forward for patients with PMR.
Article: https://www.nejm.org/doi/full/10.1056/NEJMoa2303452

Monday Oct 23, 2023
E103: Len Calabrese on Monoclonal Antibodies for COVID-19
Monday Oct 23, 2023
Monday Oct 23, 2023
This week I took a twitter disagreement from the impersonal world of twitter to the podcast world of a back and forth conversation. Really enjoyed talking to Dr. Len Calabrese about monoclonal antibodies, FDA regulatory pathways, and life in general.

Monday Oct 16, 2023
E102: Unintentional Unblinding in Rheumatic Disease Trials
Monday Oct 16, 2023
Monday Oct 16, 2023
Excited to share an editorial that I wrote along with Cody Bruggemeyer and Desh Nepal, two trainees with me at the Medical College of Wisconsin. We discussed what I believe to be a pervasive (but seldom discussed) issue in rheumatology RCTs: unblinding. I suspect many of our studies suffer from this. Have a listen!

Monday Oct 02, 2023
E101: Pred v Colchicine for CPPD: COLCHICORT
Monday Oct 02, 2023
Monday Oct 02, 2023
Happy to share the FIRST randomized trial in CPPD today. It's kind of a weird study but worth a quick discussion.
https://www.sciencedirect.com/science/article/pii/S2665991323001650

Monday Sep 18, 2023
E100: ADVOCATE Health Related Quality of Life
Monday Sep 18, 2023
Monday Sep 18, 2023
This week I dive into the health related quality of life measures that were reported in the ADVOCATE study. I found them overall somewhat convincing and they have affected my practice. Have a listen and be sure to follow along. Find my work at ebrheum.com

Thursday Sep 07, 2023
E99: Hospital Problems
Thursday Sep 07, 2023
Thursday Sep 07, 2023
Quick episode this week from a recent Perspective piece I had published in the New England Journal. Have a listen or a read!
https://www.nejm.org/doi/full/10.1056/NEJMp2304828

Thursday Aug 24, 2023
E98: Key Opinion Leaders & ILD Guidelines
Thursday Aug 24, 2023
Thursday Aug 24, 2023
Podcast this week discussing key opinion leaders (KOLs) and pharmaceutical companies. Please subscribe to my newsletter (ebrheum.com) and be sure to share the podcast with friends!

Thursday Apr 27, 2023
E97: Does allopurinol reduce CVD? The ALLHEART Study
Thursday Apr 27, 2023
Thursday Apr 27, 2023
Nice quick RCT rundown this week, covering the ALLHEART study, a pragmatic RCT of urate lowering therapy to reduce cardiovascular disease. Quick listen for a useful teaching point!
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)01657-9/fulltext

Thursday Apr 13, 2023
E96: Long COVID - Where to After Norway?
Thursday Apr 13, 2023
Thursday Apr 13, 2023
Today I cover the recently published long-COVID study from Norway. It's a great paper that challenges much of the prevailing wisdom. I think there are some interesting limitations, but anyone who sees post COVID patients (aka all of us) would do well to read it. Or have a listen here!
PDF: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2802893

Thursday Mar 30, 2023
E95: Rituximab or Cyclophosphamide in ANCA Vasculitis
Thursday Mar 30, 2023
Thursday Mar 30, 2023
Fun study this week from JAMA Network Open and the French Vasculitis Study Group. They used a target trial emulation (one of my favorites) to ask whether RTX > CYC in AAV (another one of my favorites). I tried to use this to compare between observational and randomized data.
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2799018